

# Ekso Bionics Analyst Day December 6, 2016

# Objectives

- Present Good Shepherd's overall experience with Ekso GT.
- Explain the underlying motor recovery principles that support the use of lower extremity robotic technologies.
- Present the process used to evaluate new technologies and determine final purchasing decision.
- Present the clinical, strategic, and financial impacts related to Ekso GT

# Good Shepherd Rehabilitation Network

- Founded in 1908 in Allentown, Pennsylvania
- Nationally recognized not-for-profit rehabilitation leader
- Modern Healthcare – Ranking of rehab providers by net revenue – GS is 3<sup>rd</sup> largest NFP and 8<sup>th</sup> largest overall rehab provider in the country
- More than 60,000 people treated annually at more than 60 locations throughout the Lehigh Valley and Philadelphia regions
- International leader in the use of rehabilitation technology



# New Technology Selection Process

- Is the technology clinically effective and does it enhance a patient's ability to recover function?
- Is the technology consistent with Good Shepherd's model of care?
- What is the clinical evidence?
- Does the pro forma demonstrate a satisfactory ROI? What is the projected payback time frame?
- What is the margin impact?
- Will the product under evaluation drive incremental patient volume , contribute to market share growth, and overall strategic plan?
- What is the proposition value for Good Shepherd?

# Rehabilitation is Changing

- For the past 75 years, compensation for loss of function was the primary focus of rehabilitation
- The central nervous system was thought to be unresponsive to change and incapable of recovery
- However, research has shown that the brain and spinal cord are indeed plastic and can develop new neuronal interconnections so that new functions can be acquired and restored - **Neuroplasticity**

# Neuroplasticity

- It represents the adaptive capacity of the central nervous system to modify its own organization and function.
- It is the ability of neurons in the CNS to respond to changes in their environment.
- The CNS may respond to this stimuli by reorganizing its structure, function, and/or neural connections.
- Neuroplasticity is present in both healthy and damaged CNS.

# Neuroplasticity in Healthy CNS

- Musicians – how do I get to Carnegie Hall? “practice, practice, practice”.
- Athletes – practice fundamentals – over and over and over.
- Why does this work? Muscles can’t think – its the hardwiring of the CNS through repetition of activity that leads to improvement in performance.

# Neuroplasticity

Evidence for neuroplasticity has been well demonstrated

- Skill acquisition through **practice** has been demonstrated to be a critically important variable (if not the most important variable) in the learning of motor skills and the promotion of neuroplasticity.
- **Task specificity** - if you want to improve walking, then practice walking.
- Promote body movements performed in a relatively **normal biomechanical** position and manner.
- Utilize techniques that **minimize compensation** and promote use of impaired body segment.
- **Task intensity.**



## Evaluation Process – How and Why Good Shepherd Selected Ekso

- Normalized biomechanical position throughout gait.
  - Reciprocal gait
  - Achieves hip extension – up to 7 degrees
  - Challenges balance recovery
- Variable assistance
- Can be used with multiple diagnoses :
  - SCI (Complete / Incomplete)
  - Stroke
  - Brain Injury

# Good Shepherd's Results with Ekso GT

- Clinical
- Strategic
- Financial


## Results - Clinical

- Good Shepherd has three Ekso GT – 2 designated for outpatient use; 1 dedicated for inpatients
- IP - used primarily for stroke
- OP – used for SCI; Stroke; Brain Injury; MS
- Each Ekso GT is used approximately 7 hours daily
- Clinically – Ekso GT has been a major success
- Great enhancement to our functional recovery model of care.
- Ekso GT is not an end product, but a therapy tool that enables patients to maximize their recovery and ability to walk unaided or with as little assistance as possible

## **Title: Recovery rates of motor functioning for acute rehabilitation inpatients with stroke who received exoskeleton-assisted locomotor training compared to historical controls**

- **Objective:** The aim of this study was to describe the group recovery trajectory for persons with stroke who received inpatient locomotor training with a powered exoskeleton (**Ekso - GT**) compared to historical controls who received other methods of locomotor training.
- **Research Question:**
  - Does the rate of change of motor FIM score differ by locomotor training group?
  - Does the **Ekso-GT** robotic device contribute significantly to enhanced motor and functional recovery in the inpatient rehabilitation setting for individuals who have sustained a stroke?
- **Participants:** Acute rehabilitation hospital inpatients with acute stroke.
- **Interventions:** Locomotor training with a powered exoskeleton versus conventional methods which include over-ground training with and without body-weight support.
- **Main Outcome Measures:** Functional change from admission to discharge as measured by the 13-item Motor subscale of the FIM™ System.


## GSRH Motor FIM 13 Change - Stroke Inpatients Ekso vs. Non-Ekso




# Results - Strategic

## Medicare Moves Aggressively to Value-Based Payments

- Department of Health and Human Services has announced performance goals and timelines for the transition of Medicare payments from volume to value.
- They also introduced a partnership to encourage private payers, employers, hospitals and physicians to adopt similar goals.



*"We are dedicated to using incentives for higher-value care, fostering greater integration and coordination of care and attention to population health, and providing access to information that can enable clinicians and patients to make better-informed choices." – Sylvia Burwell, HHS Secretary*



Historical Performance

Goals

## Impact of Healthcare Transformation on Post Acute Services

- Bundled payment and ACO incentives are moving post-acute patients to lowest cost setting (equation = lowest episode spend and readmissions)
  - Pressure on post acute rehab cases to lower Length of Stay.
- Strong demand for high acuity rehab will continue requiring niche expertise and technologies - - anticipate industry consolidation over time and destination centers emerging for:
  - Spinal Cord
  - Severe Stroke
  - Traumatic Brain Injury
  - Major Multiple Trauma
- Health systems looking to more tightly manage episodes via care continuum alignment.



## Patient Placement Matters More Than Ever Before

### Patient Placement Impacts:

- Length of stay/Medicare profitability
- Lowering “Episode” cost for success under growing bundle arrangements and VBP metrics
- Increased revenue to owned PAC assets (e.g., Home Health, Rehab Units)
- Reducing readmission and penalties
- Building strategic relationships for success under payment transformation (Medicare, Medicaid, private payor bundles)



# The Impact of Change is Always

**OVERESTIMATED**  
in the

**SHORT TERM**

**AND**

**UNDERESTIMATED**  
in the

**LONG TERM**

## Results - Strategic


- Challenge faced by Good Shepherd
  - rehabilitation very competitive locally
- Developed strategic plan to differentiate by focusing on catastrophic rehabilitation – SCI/Stroke/Brain Injury
- Goal was to become a destination center for catastrophic rehabilitation
- Goal was to increase Good Shepherd's market service area from local to regional / national
- Ekso GT is one of several innovative technologies that Good Shepherd uses to drive functional recovery
- Ekso GT is the cornerstone of the Locomotor Training Program

The Ekso Has Taken Good Shepherd's Patients  
**BEYONDLIMITS.**  
*3,000,000 Steps and Counting*

GOOD SHEPHERD  
REHABILITATION 



# Results - Strategic





## Results – Financial

### 5 Year Financial Performance / Per Ekso

<b>Total Capital Investment</b>	<b>\$ 150,000</b>
<b>5 Year Contribution Margin / EBITDA</b>	<b>\$ 513,342</b>
<b>5 Year Net Income</b>	<b>\$ 394,839</b>
<b>Pay Back Period - Undiscounted</b>	<b>2 Years</b>
<b>Net Present Value</b>	<b>\$ 466,478</b>
<b>IRR</b>	<b>53%</b>

THANK YOU

